Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
Adicet开放了ADI-270在转移性/爱文思控股透明细胞肾细胞癌的第一阶段临床试验的招生；这是第一种进入临床试验的伽马delta CAR t细胞疗法，有潜力针对实体肿瘤；初步第一阶段临床...
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical Data Expected In The First Half Of 2025
艾切托开放对转移性/爱文思控股透明细胞肾细胞癌的ADI-270第一阶段临床试验的招募；首个有潜力解决实体肿瘤的伽马δ CAR t 电芯疗法进入临床试验；初步第一阶段临床数据预计在2025年上半年发布。
First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials
首个有潜力解决实体肿瘤的伽马δ CAR t 电芯疗法进入临床试验。
Preliminary Phase 1 clinical data expected in the first half of 2025
初步第一阶段临床数据预计在2025年上半年发布。
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).
艾切托公司（纳斯达克：ACET）是一家临床阶段的生物技术公司，专注于发现和开发用于自身免疫疾病和癌症的异体伽马δ t 电芯疗法，今天宣布对转移性/爱文思控股透明细胞肾细胞癌（ccRCC）患者进行ADI-270第一阶段临床试验的招募已开启。
资讯热榜
更新时间